Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia

被引:111
作者
Kaefer, Aksana [1 ]
Yang, Jianning [1 ]
Noertersheuser, Peter [2 ]
Mensing, Sven [2 ]
Humerickhouse, Rod [3 ]
Awni, Walid [1 ]
Xiong, Hao [1 ]
机构
[1] AbbVie Inc, Dept Clin Pharmacol & Pharmacometr, N Chicago, IL 60064 USA
[2] AbbVie Deutschland GmbH & Co KG, Pharmacometr, D-67061 Ludwigshafen, Germany
[3] AbbVie Inc, Oncol, N Chicago, IL 60064 USA
关键词
Navitoclax; ABT-263; Pharmacokinetic; Pharmacodynamic model; Thrombocytopenia; Platelet; BCL-2; FAMILY;
D O I
10.1007/s00280-014-2530-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Navitoclax is a first-in-class, orally bioavailable, targeted Bcl-2 family protein inhibitor and promotes apoptosis. Thrombocytopenia is a primary dose-limiting toxicity of navitoclax which exhibited a distinct time profile in circulating platelets from that caused by traditional chemotherapies. A population pharmacokinetic/pharmacodynamic (PK/PD) model was developed to describe the pharmacokinetic of navitoclax as well as the time course of the platelet counts in cancer patients receiving navitoclax. Data from 256 patients who received oral navitoclax (dose range 10-475 mg) as a 14/21-day schedule or a continuous once daily (QD) schedule were used to construct the model using NONMEM. The PK model was a two-compartmental model with a lag-time and a transit compartment in absorption. The PD model was a semi-physiological model that comprised a progenitor cell compartment, three transition compartments representing the maturation chain in the bone marrow and a peripheral blood compartment. Compared with the previously published models, the model established in this analysis applied a different feedback mechanism and introduced a new concept of progenitor cell "pool", which describes a large pool of platelet progenitor cells at the beginning of navitoclax treatment. The PD model was able to describe a slight downward trend of platelet counts over the long-term navitoclax treatment as observed in around 8 % of the patients and the initial drop in platelets seen in our Phase 1/2a studies. We have developed a new semi-physiological platelet model for describing fast drop of platelets after initial navitoclax administration and long-term decline of platelets after continuous administration of navitoclax.
引用
收藏
页码:593 / 602
页数:10
相关论文
共 12 条
  • [1] Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer
    Davids, Matthew S.
    Letai, Anthony
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (25) : 3127 - 3135
  • [2] Eradat H, 2012, ASH
  • [3] Model of chemotherapy-induced myelosuppression with parameter consistency across drugs
    Friberg, LE
    Henningsson, A
    Maas, H
    Nguyen, L
    Karlsson, MO
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (24) : 4713 - 4721
  • [4] Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
    Gandhi, Leena
    Camidge, D. Ross
    de Oliveira, Moacyr Ribeiro
    Bonomi, Philip
    Gandara, David
    Khaira, Divis
    Hann, Christine L.
    McKeegan, Evelyn M.
    Litvinovich, Elizabeth
    Hemken, Philip M.
    Dive, Caroline
    Enschede, Sari H.
    Nolan, Cathy
    Chiu, Yi-Lin
    Busman, Todd
    Xiong, Hao
    Krivoshik, Andrew P.
    Humerickhouse, Rod
    Shapiro, Geoffrey I.
    Rudin, Charles M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07) : 909 - 916
  • [5] A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model
    Quartino, Angelica Linnea
    Friberg, Lena E.
    Karlsson, Mats O.
    [J]. INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 833 - 845
  • [6] Rai KR, 2000, CANC MED
  • [7] Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
    Roberts, Andrew W.
    Seymour, John F.
    Brown, Jennifer R.
    Wierda, William G.
    Kipps, Thomas J.
    Khaw, Seong Lin
    Carney, Dennis A.
    He, Simon Z.
    Huang, David C. S.
    Xiong, Hao
    Cui, Yue
    Busman, Todd A.
    McKeegan, Evelyn M.
    Krivoshik, Andrew P.
    Enschede, Sari H.
    Humerickhouse, Rod
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05) : 488 - 496
  • [8] Serby M, 2013, GREAT LAK DRUG MET D
  • [9] Role of Bcl-2 in tumour cell survival and implications for pharmacotherapy
    Tomek, Mary
    Akiyama, Toru
    Dass, Crispin R.
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2012, 64 (12) : 1695 - 1702
  • [10] ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
    Tse, Christin
    Shoemaker, Alexander R.
    Adickes, Jessica
    Anderson, Mark G.
    Chen, Jun
    Jin, Sha
    Johnson, Eric F.
    Marsh, Kerman C.
    Mitten, Michael J.
    Nimmer, Paul
    Roberts, Lisa
    Tahir, Stephen K.
    Mao, Yu
    Yang, Xiufen
    Zhang, Haichao
    Fesik, Stephen
    Rosenberg, Saul H.
    Elmore, Steven W.
    [J]. CANCER RESEARCH, 2008, 68 (09) : 3421 - 3428